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Although autopsy studies demonstrate a high
prevalence of atherosclerosis involving the mesen-
teric arteries (6%-10%),1 symptomatic splanchnic
artery occlusive disease is uncommon. The number
of mesenteric revascularization procedures per-
formed totals less than 0.5% of all peripheral vascu-
lar reconstructions.2,3 However, the mortality asso-
ciated with acute mesenteric ischemia is high.
In 1936, Dunphy4 reviewed the medical records
of patients dying of intestinal ischemia and found
that seven (58%) of 12 had evidence of chronic
abdominal pain. This finding suggested that earlier
intervention may have prevented death and alleviat-
ed symptoms. In 1957, Mikkelsen5 described the
arteriographic appearance of the typical orificial ath-
erosclerotic lesions affecting the mesenteric arteries.
It was this same year that Shaw and Maynard6 per-
formed the first successful surgical procedure for
treatment of chronic mesenteric ischemia.
Since that time, numerous techniques have been
used to revascularize the mesenteric arteries, includ-
ing angioplasty, endarterectomy, reimplantation,
and antegrade or retrograde bypass grafting with
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Objective: Complete revascularization is recommended by many authors for treatment of
intestinal ischemia. The observation that postprandial intestinal hyperemia is limited to
the superior mesenteric artery (SMA) has suggested to us that SMA revascularization
alone should be adequate treatment. We preferentially manage intestinal ischemia with a
single bypass graft to the SMA and herein update our results using this approach.
Methods: Patients were identified from a prospectively established vascular surgical reg-
istry. Each patient was assessed for acute versus chronic intestinal ischemia, preoperative
angiographic findings, operation used, perioperative morbidity and mortality, late symp-
tomatic relief, cause of death, and life table–determined survival and graft patency. Graft
patency was determined by follow-up angiography or duplex scanning.
Results: Fifty bypass grafts to the SMA alone were performed in 49 patients (31 women,
18 men; mean age, 62 years) for treatment of intestinal ischemia. In all patients addi-
tional splanchnic arteries were available for bypass grafting. Operative indications were
acute symptoms in 21 patients, 14 of whom had bowel infarction; chronic symptoms in
26 patients; and prophylaxis in conjunction with infrarenal aortic surgery in 3 patients.
Thirty-two grafts originated from the aorta or an iliac artery, and 18 originated from an
aortic graft. There were 40 prosthetic and 10 autogenous conduits. Perioperative mor-
tality was 3% in patients with chronic symptoms and 12% overall. All survivors were
symptomatically improved. Mean follow-up was 44 months. Nine-year assisted primary
graft patency was 79%, and 5-year patient survival was 61%. Two late deaths occurred in
patients with recurrent intestinal ischemia resulting from graft occlusions.
Conclusions: Bypass grafting to the SMA alone appears to be both an effective and
durable procedure for treatment of intestinal ischemia. Our results appear equal to those
reported for “complete” revascularization for intestinal ischemia. When the SMA is a
suitable recipient vessel, multiple bypass grafts to other splanchnic vessels are unneces-
sary in the treatment of intestinal ischemia. (J Vasc Surg 2000;32:37-47.)
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autogenous or prosthetic grafts. Debate persists
about the optimal number of vessels to revascularize.
Proponents of multiple vessel or “complete” revas-
cularization maintain that although single-vessel
bypass grafting is effective in relieving symptoms ini-
tially, there may be a higher incidence of recurrent
symptoms resulting from graft failure.7,8
We continue to use single-vessel bypass grafting to
the superior mesenteric artery (SMA) whenever feasi-
ble for treatment of both acute and chronic mesen-
teric ischemia, and we believe this method to be com-
parable with complete revascularization. There are
few reports of long-term mesenteric bypass graft
patency in which objective methods were used. The
current series reports our experience and long-term
results with single-vessel bypass grafting to the SMA
with objective methods to determine graft patency.
METHODS
All patients who underwent mesenteric revascu-
larization of the SMA alone between 1985 and 1998
were identified from prospectively established vascu-
lar surgery registries at the Oregon Health Sciences
University and the Portland Department of Veterans
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Fig 1. Retrograde bypass graft from the right common iliac artery to the SMA in the C-loop config-
uration. The inset demonstrates the creation of a flange for the proximal anastomosis as described by
Wylie et al.10
Affairs Medical Center. Only six patients had multi-
ple-vessel revascularizations during this same time
period. The early results of 26 patients have been
previously reported.9 This series serves to provide
long-term follow-up on these original patients and
to add a significant number of new patients. Patients
who had embolic events were excluded. Hospital
and clinic charts were reviewed for comorbidities,
previous mesenteric revascularization, acute versus
chronic ischemia, preoperative angiographic find-
ings, operation used, perioperative morbidity and
mortality, late symptom relief, and cause of death.
Patients were considered to have acute ischemia
when they had signs and symptoms requiring imme-
diate intervention regardless of antecedent symp-
toms. All patients had postoperative angiography
before discharge from the hospital.
The preferred surgical technique was retrograde
bypass grafting from either the infrarenal aorta or
common iliac artery (usually the right), as shown in
Fig 1. A 6- or 7-mm bifurcated polyester graft was
used as a conduit whenever possible. A limb was cut
from the graft to create a flange for the proximal
anastomosis as described by Wylie et al.10 The graft
was arranged in a “C-loop” configuration to permit
an antegrade anastomosis to the SMA distal to the
point of obstruction.
Standard follow-up at our institution consisted
of biannual visits during the first year of follow-up
and annual visits thereafter. Additional information
was acquired through telephone contact with the
patients or their primary care physicians. At postop-
erative visits, patients were questioned about the
recurrence of symptoms, and their weight was
obtained. Duplex ultrasound scanning was per-
formed at each visit to document graft patency.
Angiography was performed when duplex ultra-
sound scanning suggested significant graft stenosis
or occlusion. Graft revisions were performed when
surveillance studies revealed high-grade stenosis.
Long-term graft patency and survival were deter-
mined with the life table method.11
RESULTS
Fifty bypass grafts to the SMA alone were per-
formed in 49 patients. One patient had a repeat
bypass graft in the perioperative period when the ini-
tial graft was found occluded. There were 31 female
and 18 male patients with a mean age of 62 years
(range, 13-83 years). Patient comorbidities are listed
in Table I. Twelve patients (24%) had undergone
previous attempts at revascularization including
three SMA angioplasties.
Twenty-one patients (42%) had acute ischemic
symptoms; 14 patients had segmental bowel infarc-
tion requiring bowel resection. Eleven of these 14
patients gave a history compatible with chronic
mesenteric ischemia. Twenty-six patients (52%) were
operated on electively for treatment of chronic
symptoms consistent with mesenteric ischemia
(abdominal pain and weight loss). The average
weight loss was 17 kg (range 5-36 kg). Three
patients (6%) were asymptomatic with high-grade
SMA stenosis or occlusion and had prophylactic
SMA revascularization in conjunction with infrarenal
aortic surgery.
Preoperative angiography was available for
review in 48 patients (98%). All patients had > 70%
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Table I. Comorbidities in 49 patients undergoing
SMA bypass grafting
Condition Number (%)
Tobacco use 48 (98)
Hypertension 33 (67)
Peripheral arterial disease 28 (47)
Coronary artery disease 22 (45)
Diabetes 5 (10)
Fig 2. Preoperative lateral aortogram revealing tight
stenoses of the proximal SMA (dark arrows) and the ori-
gin of the celiac artery.
stenosis or occlusion of the SMA. Forty-four
patients (92%) had > 70% stenosis or occlusion of
multiple vessels (Fig 2). All patients underwent post-
operative angiography (Fig 3).
Sixteen grafts originated from the abdominal
aorta (10 retrograde, six antegrade). Sixteen grafts
originated from a common iliac artery (14 from the
right, two from the left). Twelve patients (11 with
chronic symptoms and one with acute symptoms)
had infrarenal aortic replacement surgery at the time
of their SMA bypass graft, which served as the
source of inflow. All of these patients required aortic
replacement for coexisting symptomatic lower
extremity arterial occlusive disease. The graft origins
for the remaining six patients were previously placed
aortic grafts. In 40 procedures, prosthetic grafts
were used, and in 10 procedures, reversed saphe-
nous vein grafts were used. Eight of the patients
who had reversed saphenous vein grafts had acute
ischemia, with seven requiring bowel resection.
There were six deaths (12%) in the immediate
postoperative period. Perioperative mortality was 3%
in patients with chronic ischemia and 24% in patients
with acute ischemia. Five deaths occurred in patients
with acute ischemia; four of these patients had
required segmental bowel resection for necrosis.
One patient died on the third postoperative day
(POD) as a result of graft occlusion and presumed
technical error. She had undergone SMA reimplan-
tation at a referring hospital 8 months earlier and
had SMA occlusion and prolonged ischemia. One
patient with a perforated sigmoid colon died on
POD 2 from sepsis. Three additional patients died
from multisystem organ failure. One died on POD 1
after having all but 60 cm of small intestine resected.
The remaining two patients died on PODs 4 and 6.
Both had aortic occlusion and abdominal pain and
required lower extremity revascularization in addi-
tion to SMA bypass grafting. The patient with
chronic mesenteric ischemia died on POD 3 of hem-
orrhage at the SMA anastomosis. She had under-
gone a supraceliac aorta to SMA and hepatic artery
bypass grafting 16 months earlier and had a graft
infection and a pseudoaneurysm at the hepatic
artery anastomosis.
There were three graft occlusions in the immedi-
ate postoperative period. Two of these occurred in
patients with acute ischemia. One patient died as dis-
cussed above. Another had a right hemicolectomy
and graft removal, the remaining intestine was
viable, and no additional revascularization was per-
formed. The third, a patient with chronic mesenteric
ischemia, had another graft placed to the SMA. A
fourth patient had an SMA stenosis distal to the
graft anastomosis detected on postoperative
angiogram. This graft was extended during the same
hospitalization.
Twenty-one additional complications occurred
in 14 patients. Pulmonary complications were the
most common (8) and consisted of multifactorial
respiratory failure (3), adult respiratory distress syn-
drome (2), pneumonia (2), and mucous plugging
(1). Two patients had evidence of congestive heart
failure; none had myocardial infarction. Two
patients had strokes. Three patients had wound
complications consisting of cellulitis, hematoma,
and dehiscence (one of each). Additional complica-
tions included pneumothorax resulting from central
line placement attempts (2), urinary tract infections
(2), hemorrhage from a prepyloric ulcer (1), and
intra-abdominal abscess (1). The average lengths of
hospitalization and intensive care unit care were
32.7 and 5.2 months, respectively, for patients with
acute ischemia and 18.7 and 3.4 months, respective-
ly, for patients with chronic ischemia.
Three patients experienced late graft occlusions
at 7, 19, and 51 months. Two of these occlusions
resulted in death; one patient underwent successful
repeat bypass grafting to Riolan’s arch. One addi-
tional patient had high-grade graft stenosis on a sur-
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Table II. Life table–determined assisted primary graft patency
Interval At risk Occlusions Withdrawn Interval patency Cumulative patency SE
0-1 mo 50 3 8 0.935 0.935 0.0364
1 y 39 1 9 0.971 0.908 0.0443
2 y 29 1 5 0.962 0.873 0.0543
3 y 23 0 6 1 0.873 0.0543
4 y 17 0 4 1 0.873 0.0543
5 y 13 1 5 0.905 0.79 0.093
6 y 7 0 1 1 0.79 0.093
7 y 6 0 2 1 0.79 0.093
8 y 4 0 1 1 0.79 0.093
9 y 3 0 2 1 0.79 0.093
veillance duplex scanning examination performed 37
months postoperatively. The stenosis was confirmed
by angiogram, and the patient underwent successful
revision.
There were nine late deaths. Two resulted from
graft occlusions as discussed above. Five additional
deaths were due to myocardial infarction, renal fail-
ure, pneumonia, sepsis, and anaphylaxis. The cause
of death could not be determined in two patients.
All survivors had symptomatic improvement in
the immediate postoperative period. Mean follow-
up was 44 months. Two patients had postprandial
abdominal pain in the follow-up period. One patient
had an angiogram performed that showed a patent
graft with good runoff. The second patient had
gained 11 kg and had a duplex ultrasound scan
demonstrating graft patency. The average weight
gain was 6 kg.
Life table–determined 9-year primary assisted
graft patency was 79% (SE 0.0930), and 5-year sur-
vival was 61% (SE 0.0942) as shown in Tables II and
III. Thirteen patients were lost to follow-up an aver-
age of 40 months after their bypass graft. All surviv-
ing patients had an objective test documenting graft
patency within 1 year of the end of their follow-up
period.
DISCUSSION
Symptomatic mesenteric ischemia occurs infre-
quently. Most series of mesenteric revascularizations
include fewer than 100 patients. The number of
patients included with acute ischemia varies widely,
with most series limited exclusively to patients with
chronic ischemia. Variable techniques are used with-
in most series depending on clinical circumstances.
With such small numbers of patients and obvious
differences in patient selection, it has been difficult
to demonstrate a significant benefit of one revascu-
larization technique over others. As such, the most
any series has been able to show is that the results
achieved are comparable with others reported.
One fundamental issue in mesenteric revascular-
ization is the number of vessels to revascularize. In
reports from the Mayo Clinic, it was first suggested
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Fig 3. Preoperative angiogram revealing a large meandering mesenteric artery (left) and postoperative
angiogram in the same patient with a retrograde bypass graft filling the SMA and branches.
Table III. Life table–determined survival
Interval At risk Deaths Withdrawn Interval survival Cumulative survival SE
0-1 mo 49 6 3 0.874 0.874 0.0482
1 y 40 0 9 1 0.874 0.0482
2 y 31 4 3 0.864 0.755 0.0691
3 y 24 0 6 1 0.755 0.0691
4 y 18 2 2 0.882 0.666 0.0849
5 y 14 1 4 0.917 0.611 0.0942
6 y 9 1 1 0.882 0.539 0.1071
7 y 7 0 3 1 0.539 0.1071
8 y 4 0 1 1 0.539 0.1071
9 y 3 0 2 1 0.539 0.1071
that complete revascularization resulted in decreased
symptomatic recurrence,7 and later that graft patency
and survival in patients with three-vessel revascular-
ization were improved compared with single-
vessel revascularization.8 These two studies were
limited to patients with chronic mesenteric ischemia
and did not use objective methods to determine
graft patency. In the latter study, McAfee et al8
noted that symptoms of recurrent ischemia were an
unreliable measure of graft patency because two of
their three early occlusions were asymptomatic.
Although these retrospective studies suggest that
complete revascularization resulted in fewer recur-
rences and deaths (deaths were not explicitly linked
to recurrent mesenteric ischemia), their results were
not statistically significant.
Despite the lack of convincing data to support
the necessity of multiple bypass grafts, several
authors have advocated complete revasculariza-
tion.3,12,13 Calderon et al12 reported results with 20
patients in 1992. They had two early occlusions
(10%); there were no deaths or symptomatic recur-
rences during a mean follow-up of 3 years. In two
additional series, researchers reported fewer recur-
rences in patients with complete revascularization.
Rheudasil et al3 found no symptomatic recurrences
in patients who had complete revascularization. Six
(16%) of 38 patients did have late revascularization
failures (three were symptomatic); three failures
occurred in patients with SMA revascularization
alone. Johnston et al2 had three (14%) recurrences
in 21 patients. These included two deaths in patients
with single-vessel bypass grafting and one patient
with multiple-vessel bypass grafting who required
repeat bypass grafting. Graft thrombosis only
occurred in grafts placed in the retrograde position.
The technique of placement was not described.
These series included only patients with chronic
ischemia. Only symptomatic recurrences were ade-
quately reported; no routine objective follow-up was
obtained.
Proponents of single-vessel revascularization
have reported similar long-term results. Series from
France have shown SMA reconstruction to be 
a durable form of treatment for intestinal
ischemia.13,14 Kieny et al13 performed 60 direct or
indirect (using a short prosthetic segment) reim-
plantations of the SMA (10% of patients had addi-
tional vessels reconstructed) in patients with athero-
sclerotic lesions of the visceral arteries. Their mean
follow-up was 8.5 years. Five patients (8.3%) had
recurrences, and one patient died as a result. The 5-
year actuarial survival was 69.6%. Cormier et al14
performed 103 reconstructions of the SMA for ath-
erosclerotic occlusive disease. Thirty-seven percent
of patients had additional vessels reconstructed. Late
ischemic complications appeared unrelated to the
number of vessels revascularized. Five patients had
late ischemic complications; four of these had celiac
artery revascularization in addition to the SMA
reconstruction. In these studies most patients were
men, and nearly one third of patients in each study
were asymptomatic.
In the United States, favorable results for single-
vessel revascularization have been reported.9,15
Stanton et al15 performed 20 reconstructions in 17
patients and at 60.9 months found no symptomatic
recurrences. At the University of California, San
Francisco, the preferred method of mesenteric
revascularization has been transaortic endarterecto-
my, with antegrade aortoceliac bypass grafting
reserved for older or poor-risk patients.16,17
Transaortic endarterectomy usually involved revas-
cularization of both the celiac axis and the SMA. No
difference was found in recurrence rates between
the two techniques with 86% of patients in both
groups being asymptomatic at 5 years, and it was
concluded that durable relief of symptoms did not
appear to correlate with the number of visceral
arteries repaired.17
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Table IV. Recent mesenteric revascularization outcomes
Patients Perioperative Perioperative Late % Late deaths 5-y survival†
Author (% acute) mortality (%) occlusions (%) occlusions* from ischemia (%)
Current series 50 (42) 12 6 3 22 61
Mateo et al 199925‡ 85 (0) 8 3.5 16 21 64
Kihara et al 199924‡ 42 (0) 10 0 4 33 70
Moawad et al 199723‡ 24 (0) 4 4 2 25 71





At our institution, the surgical approach to man-
aging acute and chronic mesenteric ischemia has
changed in the last two decades.9,18 In 1984, Baur
et al18 reported a series of 23 patients who under-
went complete revascularization whenever possible.
Perioperative mortality was 9%, and during a mean
follow-up of 2 years 9.5% of patients had graft fail-
ures. At that time we were of the opinion that
incomplete revascularization may not alleviate symp-
toms in all patients and that progression of disease in
nonrevascularized vessels may lead to recurrent
symptoms. However, physiologic studies of the celi-
ac and mesenteric arteries have since demonstrated
that postprandial hyperemia is limited to the
SMA.19-21 This finding, in combination with the
usual disease pattern (ostial lesions) and extensive
collaterals, has led us to believe that in most patients
a single bypass graft to the SMA should alleviate
symptoms initially and be durable over time. In
1994, Gentile et al9 reported 26 patients who had
29 isolated bypass grafts to the SMA for intestinal
ischemia (23 chronic, 5 acute, 1 asymptomatic).
Perioperative mortality was 10%. The mean follow-
up was 40 months, and the life table–determined 4-
year primary graft patency rate and survival rate were
89% and 82%, respectfully. This compared favorably
with contemporary reports in the literature.9 On the
basis of these data we have continued to perform
revascularization of the SMA alone for treatment of
intestinal ischemia.
In the current study the usual sex prevalence of
women to men was noted (1.7:1). Patient comor-
bidities were similar to those reported in recent
series.22-25 The extent of disease as shown by preop-
erative angiography was also similar; 92% of patients
had significant involvement of two or more ves-
sels.22-25 This series does differ from others with
respect to the larger number of patients with previ-
ous attempts at revascularization (24%), the higher
percentage of patients with acute ischemia (42%),
and the higher percentage of patients requiring
bowel resection (28%). Our overall perioperative
mortality (12%), however, is comparable with other
recent series (Table IV). Perioperative mortality was
3% for patients operated on electively. Mateo et al25
recently found significantly increased perioperative
morbidity (including death) using univariate analysis
in patients who underwent complete revasculariza-
tion for treatment of intestinal ischemia.
When available, we choose the infrarenal aorta or
a common iliac artery for the origin of the bypass
graft. To date, it has not been necessary to revise or
replace a graft resulting from progression of disease
in the inflow artery. Dacron was the conduit of
choice in this series. Although Dacron grafts have
not conclusively been shown to be superior to vein
grafts, we believe they are less prone to kink when
placed in the retrograde position.
We do not perform revascularization for asymp-
tomatic lesions except when they occur in patients
who require aortic operations. In this group of
patients, acute intestinal ischemia after aortic surgery
has been well documented.26
The incidence of perioperative graft occlusions
(6%) reported herein is similar to recent series, only
one of which contained a significant number of
patients presenting with acute ischemia (Table IV).
Three graft occlusions occurred during long-term
follow-up and resulted in death in two patients,
accounting for 22% of late deaths. In this series the
number of symptomatic late graft occlusions, the
number of deaths attributable to recurrent ischemia,
and the life table–determined survival were also
comparable with other recent series using more
complete visceral revascularizations (Table IV).
Although acute mesenteric ischemia is accompanied
with a higher perioperative mortality rate, McMillan
et al22 found no differences in long-term patency of
bypass grafts among patients with acute or chronic
ischemia. Two of the three late occlusions in this
series occurred in patients whose initial graft was
placed for chronic mesenteric ischemia; however,
one of these occluded in the perioperative period
and had to be replaced. Revascularization of the
SMA alone continues to compare favorably with
more complete splanchnic revascularizations 
(Table V).
Several authors have noted that symptoms are an
insensitive measure of graft failure.8,22 With improve-
ments in duplex scanning, several studies, including
the present one, now have objective data for long-term
graft patency (Table V). We have surgically revised one
SMA graft according to an abnormality detected by
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Table V. Series comparisons of objectively deter-
mined graft patency
Follow-up Patency† 
Author Patients Revisions (y)* (%)
Current series 50 3 9 79
Mateo et al 199925 84 9 5 71
Kihara et al 199924 42 7 2 73
Moawad et al 199723 24 1 5 78
McMillan et al 199522 25 0 5 88
*End point of significance by life table, SD less than 10%.
† Life table–determined.
duplex ultrasound scanning surveillance. An addition-
al bypass graft in a patient with an isolated inferior
mesenteric artery has been surgically revised on the
basis of duplex scanning surveillance and a third
mesenteric graft treated with angiographic techniques
for an asymptomatic high-grade stenosis.
In summary, symptomatic mesenteric ischemia
remains uncommon. Recognition and treatment of
the syndrome of chronic mesenteric ischemia may
avoid progression to acute ischemia, alleviate symp-
toms, and provide durable long-term relief. This
may be accomplished by a number of techniques.
Single-vessel bypass grafting to the SMA compares
favorably in terms of graft patency, death from recur-
rent ischemia, and survival with recent reports of
intestinal revascularizations using bypass grafts to
multiple arteries. When the SMA is a suitable recip-
ient vessel, additional bypass grafts to other splanch-
nic vessels are unnecessary.
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DISCUSSION
Dr Linda M. Reilly (San, Francisco, Calif). President
Dilley, members and guests:
I would like to thank the authors for providing me
with a preliminary version of their paper well in advance of
this meeting. However, I never did receive the final ver-
sion of the paper, so what follows are my preliminary com-
ments and my preliminary questions.
The authors present a series of 49 patients who under-
went retrograde SMA bypass with a perioperative mortal-
ity of 12% and a graft failure rate—that is, occlusion or
stenosis requiring further operation—of 16%: 8% in the
perioperative period and 8% during follow-up. They state
that these results are comparable with other reported
series and conclude that, and I quote “additional bypass
grafts to other splanchnic vessels are unnecessary.”
The results of this series are good and are comparable
with other reported series. In fact, when I superimpose the
life table of our single-vessel bypass visceral ischemia
patients on that of this series, the curves are identical. The
difference, of course, is that most of our single-vessel
bypasses use the celiac, while those in this series use the
SMA. However, I do have a few questions and comments.
1. You really have only 49 patients, not 50. The patient
whose graft occluded early postoperatively and was
redone had reached the primary end point of the
study, graft patency. His/her second bypass should
not be considered a primary graft.
2. How many visceral revascularizations were performed
at your institution during this time interval? What pro-
portion of the total is represented by the retrograde
SMA bypass group? If there is a significant group of
patients who underwent some other operative tech-
nique, do you have clinical or anatomic guidelines for
choosing the retrograde SMA bypass?
3. You state that preoperative anteriograms were avail-
able for review for 48 of the patients. Do you have
information regarding the status of the visceral collat-
eral routes prior to your SMA bypass? By that I mean
the celiac (SMA and the IMA) SMA routes.
4. In this series 42% of the patients had acute mesenteric
ischemia, and 24% of patients underwent prior mesen-
teric revascularization. While I think that this makes
your results even more impressive, I also think it sug-
gests that this may be a relatively select group, and
that retrograde SMA bypass may be particularly
appealing in the acute setting, with a sick and unstable
patient and in the setting of a difficult reoperation
where not all other vessels may be available. You state
that other vessels were available in all patients, but
there is available and then there is available. Fully half
of our reoperations involve bypass to only a single vis-
ceral artery. Do you have more detail about the prior
visceral revascularizations? In choosing the SMA were
you choosing an artery not previously operated on?
How many of the patients who had presented acutely
also had prior revascularization?
5. You present only the assisted patency life table, which
allows you to skip the two patients who were reoper-
ated for graft stenosis. I would suggest that you
should also present a life table of graft durability. I do
not think that it will be that much worse with only two
more events and it gives your reader a more accurate
picture of the primary end point of graft failure requir-
ing further treatment.
6. Finally, the real question is what is the most durable
operation for visceral ischemia? I would suggest that
you have not established that because of the small size
of your series. The same limitation applies to all other
published series, including our own. Our 1991 paper
states that our results suggest that the number of vis-
ceral arteries repaired did not correlate with durability.
However, our overall symptom relief at 5 years was 86%,
while that for our single-vessel visceral bypasses was only
76%. While this difference was not statistically signifi-
cant, that is likely due to the fact that we only had 23
patients in the single-vessel bypass group. Therefore, I
do not agree that you can conclude that bypasses to
other vessels are categorically “unnecessary.”
In closing, when Dr Moneta assigned me to discuss
this paper, he asked me to be nice. Those of you paying
close attention to the program will note he tried to ensure
my compliance with that request by assigning Dr Porter to
discuss our paper. I understand that we have dodged that
bullet, but I will comply with Dr Moneta’s request and
finish by saying I enjoyed this excellent paper, with its very
good results from the talented group at OHSU.
Dr Matthew Foley. Thank you for your comments, Dr
Reilly. I will do my best to answer the questions as I
understand them. I may use Dr Moneta’s wisdom and
experience, though, to help me out.
I believe your first point was that we should have only
included 49 patients in the study because of the one periop-
erative graft inclusion. This may be correct. All I can say is
that when we reentered the patient, we considered the
patient new and did include the occlusion in our overall data.
The second question I believe was during the same
time period: how many patients had other procedures per-
formed for a mesenteric revascularization? There were
about a half dozen patients who had other procedures per-
formed during this time period, and this was usually for
special circumstances. For example, they had previously
undergone bypass elsewhere, and we did not feel that the
SMA was available or the SMA runoff was not good or
there were not good collaterals. It was definitely a minor-
ity of the operations we performed.
Concerning our angiographic findings, I do not have
detailed information on the number of vessels that were
available on all patients. Suffice it to say all the patients did
have additional options. We could have placed additional
grafts in all the patients whose angiograms we reviewed.
Did we have a select group of patients because a num-
ber presented with acute ischemia and some of those had
had previous grafts and perhaps SMA was the only vessel
available? Perhaps that is the case.
Anything to add to that, Dr Moneta, regarding
whether our patients were preselected for SMA bypass?
Dr Gregory Moneta. No. They were not preselected for
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SMA bypass. There were a few patients in whom other ves-
sels revascularized, which would have been more difficult,
but it is just like any other aspect of surgery. The difficulty
depends on how much effort you want to put into it.
The SMA was always chosen as the preferential vessel
unless it was just not technically considered possible, and
Dr Foley alluded to that. We have a few bypasses to isolate
IMAs, but mostly to the SMA. We do not have any bypass-
es as far as I can recall just to the celiac like you tend to do.
Dr Foley. In the patients who presented with acute
ischemia who had had previous bypasses, I do not have
details as to exactly what their operations were and how
many vessels were bypassed and how many of those were
patent. Certainly they were symptomatic at the time of
their occlusion.
As you pointed out, the size of our series is small.
There are probably a good couple of dozen series in the
literature, and only a couple of these have patient groups
that include more than 100 patients, which definitely lim-
its the applicability of our results.
I think chronic mesenteric ischemia is uncommon in
the clinical practice of vascular surgery. Less than 1% of
peripheral reconstructions is performed for mesenteric
ischemia. So it is hard to come up with a standard
approach in all patients. What single-vessel SMA bypass
has allowed us to do is at least have a starting point, a pro-
cedure that is generally applicable to the majority of
patients that we see. And I think our results, although they
are perhaps not the best in the literature, are definitely
comparable.
Dr Christian de Virgilio (Los Angeles, Calif). I enjoyed
your paper very much. I have a couple of questions.
First, I recall that you reviewed your earlier experience
in the Archives of Surgery several years ago, and my ques-
tion is have you looked at the early results compared with
your current results with regard to patient characteristics,
patency rates, etc? In other words, has there been any type
of a learning curve?
Second, I recently had a patient myself, an 80-year-old
woman with congestive heart failure with a coral reef aorta
all the way up to the diaphragm who had occlusion of
both her celiac and SMA and a 90% IMA stenosis. When
the bowel was rotated, the entire bowel turned blue. We
ended up taking a graft off the only soft spot in her com-
mon iliac, then went to her IMA first to get the bowel
reperfused, and then the SMA.
So I think my question is, although I think this is an
ideal situation, the isolated SMA bypass, would you not
think that there might be some instances where more
complete revascularization would be indicated?
Dr Foley. Dr de Virgilio refers to Dr Gentile’s paper
that was published in the Archives. Four-year graft 
patency was in the 80% range, and I believe patient 
survival was pretty comparable with that. There is not
much difference at all between the two series, and I do not
think we have necessarily gotten better over time. I think
the results basically confirm what we reported earlier.
In regard to the second question about whether there
are some instances where perhaps additional bypasses
would be necessary, I do not think we found that to be the
case in our series. It is interesting to point out that in one
of these recent series, univariate analysis showed an
increase in perioperative morbidity including mortality in
patients who underwent more complete revascularization.
Dr Roy Fujitani (Irvine, Calif). Over the last 10 years
or so we have had a more modest experience with regard
to revascularization for patients presenting with intestinal
ischemia. On occasion patients presented with acute
mesenteric ischemia requiring bowel resection. We have
had reason to use reverse saphenous vein as in your series.
I think one fifth of your patients ended up having that.
However, we have also found that these reverse saphenous
veins do not seem to do as well as prosthetic grafts.
I noticed that you had said you had had two late
occlusions that resulted in death as well as other compli-
cations. I wonder if you could tell me whether or not these
were prosthetic veins or vein grafts and whether or not
you follow these grafts differently depending on what the
original graft is.
Dr Foley. Thank you. Our occlusions occurred in
patients with prosthetic grafts, and we followed up all
patients similarly whether they had vein or prosthetic
grafts placed.
Dr Moneta. I have a policy. Even if it is acute ischemia,
I will not put in a poor vein. I will still put in a prosthetic
in those patients. If the graft gets infected, that is a prob-
lem to deal with later, but putting in a poor vein graft
instead is not a substitute for a prosthetic, even in the face
of intestinal necrosis.
Dr Robert Rutherford (Denver, Colo). I think an
important aspect of this paper is that you have reported
your patencies confirmed by duplex imaging or in some
cases arteriography, and that is a real step forward. A lot of
the patency rates reported in the literature are based on
clinical signs of recurrence and then investigated by arteri-
ography. With multiple vessel revascularization, that is not
a valid way to follow patency. So I think you are to be
commended for that, and I hope others will follow suit in
the future.
In the past I have selectively used just a single SMA
revascularization, but in many cases I have chosen another
technical option, which is SMA reimplantation, which if
you mobilize the SMA below the obstruction coming in
from the left lateral approach, you can swing it down, reim-
plant it on the anterior aorta, and end up with an all auto-
genous reconstruction and only one anastomosis that gets
you good patency rates if you can be sure not to let that
kink in terms of positioning it. But that is just another, I
think, good way to approach an SMA revascularization,
and I thought I would mention it for your consideration.
Dr Foley. I would just like to comment on that. The
series that I did show up there on the one big slide, all of
those series used either duplex or angiogram to confirm
their patency as well. We did not focus on graft patency
too much because in these other series where complete
revascularization was performed, our patency rates could
JOURNAL OF VASCULAR SURGERY
46 Foley et al July 2000
be the same, but their patients could fare better if they had
an additional graft that was open. I mean, if our patients
occlude, they are occluded. So we tended to look more at
our long-term survival and freedom from recurrent
ischemia.
Dr Mark Nehler (Denver, Colo). A couple of ques-
tions. One, you had a couple of patients who were asymp-
tomatic and who you went ahead and revascularized. Is
that your policy, to get lateral aortograms, and if you see
three-vessel disease, that you would aggressively go after
the asymptomatic patients?
Number two is how difficult is it to do this graft sur-
veillance in these mesenteric patients? It seems like that is
not a routine thing in a lot of vascular laboratories. Do
you have to go to angiography frequently when you can-
not get good studies or do you have to do repeat studies
frequently?
I know that in Oregon, like a lot of places, you have a
lot of your patients come from fairly geographically distant
areas, and that might complicate things as well since I
believe they have to be NPO for the studies.
Dr Foley. That is a good point. I will answer the second
question first. We definitely try to get duplexes on all the
patients at the postoperative visits, but some of them
would forget to fast and the studies can be difficult if there
is a lot of bowel gas. Most of the time the patients have
lost so much weight, the grafts are pretty easy to find, I
think. I do not have exact numbers on our percent success
rate of getting good studies, but the majority of the
patients had adequate follow-up studies.
The first question was with regard to our treatment of
asymptomatic patients who are found to have high-grade
SMA stenosis or occlusion. I will ask Dr Moneta to com-
ment on that.
Dr Moneta. Well, the answer to the first thing that
Mark talked about was with diligence and encouragement
you can study these grafts, especially the retrograde grafts.
They are not all that hard to see with the duplex scanners.
Antigrade grafts are more difficult.
Second, the revascularization of asymptomatic vessels
derives from the work of one of the members of this soci-
ety when John Connolly pointed out years ago that
patients with high-grade SMA stenoses who have
infrarenal aortic reconstructions can have necrosis of the
small bowel postoperatively. So in those particular
instances we will revise those and place a graft to the SMA
if we are doing infrarenal reconstruction in those patients.
Dr Jeffrey Ballard (Loma Linda, Calif). Just a ques-
tion about your chronic cases. In the patients with multi-
ple-vessel occlusion or disease, do you think you may have
been more likely to do a more complete revascularization
based on your approach to the vessels?
For instance, if you had done a medial visceral rotation
or a left flank in a retroperitoneal approach, you would
have had the celiac and the SMA both readily available to
you, and I am just wondering if that may have actually
changed your conclusions.
Dr Moneta. Well, if we planned to do a different oper-
ation, we might have done a different operation, I guess.
That is the only thing you can say.
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